.jpg) |
| Feijoa Photo Credit: Arina Krasnikova |
Scientific Frontline: Extended "At a Glance" Summary: Feijoa Supplementation and Blood Pressure
The Core Concept: Whole-fruit feijoa powder supplementation involves the daily dietary intake of a processed form of the feijoa fruit, which is dense in bioactive compounds such as polyphenols, flavonoids, vitamin C, and abscisic acid. It is currently being evaluated for its physiological effects on metabolic and vascular health during weight-loss interventions.
Key Distinction/Mechanism: While feijoa supplementation does not alter body weight or fasting plasma glucose trajectories beyond the baseline effects of a low-energy diet, its bioactive polyphenolic matrix—notably high in catechins—appears to independently enhance reductions in systolic blood pressure.
Origin/History: The potential cardiovascular benefits of feijoa were an unexpected, incidental discovery during the 2025 and 2026 FERDINAND randomized controlled trial conducted at the University of Auckland, which was primarily designed to investigate type 2 diabetes risk prevention.
Major Frameworks/Components:
- The FERDINAND trial framework: A six-month clinical trial structure combining an initial two-month low-energy diet to induce weight loss, followed by a four-month weight-loss maintenance phase.
- Bioactive compound analysis: The physiological evaluation of whole-fruit plant matrices, specifically targeting the metabolic and anti-inflammatory effects of polyphenols, flavonoids, and abscisic acid.
- Intention-to-treat modeling: The utilization of linear mixed-effects models to statistically analyze changes in metabolic biomarkers across randomized cohorts.
Branch of Science: Nutritional Science, Cardiovascular Physiology, and Endocrinology.
Future Application: The development and standardization of scientifically validated, feijoa-derived functional foods and nutraceuticals prescribed alongside weight-loss programs to optimize cardiovascular health in populations with obesity and prediabetes.
Why It Matters: As metabolic syndrome and prediabetes become increasingly prevalent, identifying dietary supplements that safely and demonstrably lower systolic blood pressure offers a crucial, non-pharmacological intervention for reducing the overall risk of cardiovascular disease.
.jpg) |
| Dr Ibrahim Mohamed Photo Credit: Courtesy of University of Auckland |
An unexpected finding in a university study suggests a path for more research.
A world-first clinical trial of feijoa has provided preliminary evidence of the fruit reducing blood pressure during weight loss.
The unexpected finding was incidental to studying feijoa’s potential for preventing type 2 diabetes, says Dr. Ibrahim Mohamed of the University of Auckland’s Human Nutrition Unit.
“It’s not what we set out to find, but it’s interesting and certainly warrants more research,” says Mohamed.
A study called FERDINAND investigated whether feijoa powder boosted weight loss or improved blood sugar, a marker of diabetes risk, during a six-month weight-loss program for people with prediabetes.
The research was funded under the government’s High-Value Nutrition National Science Challenge (Ko Ngā Kai Whai Painga), which aimed to boost New Zealand’s exports of health food products by scientifically validating health claims.
The company Anagenix Ltd. supplied a whole-fruit feijoa powder product called Feiolix for the study.
The research did not show any meaningful effects in connection with weight loss or blood sugar. However, systolic blood pressure—the top number in a blood pressure reading—improved more for people consuming feijoa powder than for those on a placebo.
Because the evidence was not consistent across all analyses and the study was relatively small—97 people—larger trials are needed to reach a definitive conclusion.
“Further studies in larger cohorts are warranted to fully evaluate the contribution that whole-fruit feijoa powder may make to improved blood pressure,” Mohamed and his co-authors wrote in the paper published in the journal Diabetes, Obesity and Metabolism.
The study was the world’s first long-term clinical trial of feijoa powder supplementation in humans.
Scientists are fascinated by the fruit’s potential because it contains bioactive compounds, including polyphenols, flavonoids, vitamin C, and abscisic acid (ABA), offering antioxidant, anti-inflammatory, and potentially metabolic effects.
A previous short-term clinical study in Iran pointed to the benefits of feijoa for patients with type 2 diabetes.
During the University of Auckland study, adults with raised blood sugar were given about 1 gram of feijoa powder (or a placebo) every day for six months.
Participants consumed the powder with their breakfast, either mixing it into a glass of water or into their meal.
In the first two months of the study, participants reduced their weight through a free meal-replacement program. The following four months focused on maintaining the weight loss.
Additional information: The study was conducted in collaboration with AgResearch, the Malaghan Institute, and Plant and Food Research.
Published in journal: medRxiv (Preprint)
Title: Evaluating whole fruit feijoa powder for type 2 diabetes risk prevention: the FERDINAND RCT
Authors: I.A. Mohamed, I.R. Sequeira-Bisson, J.J. Lim, L.D. Plank, R. Murphy, S.D. Poppitt, and J.L. Miles-Chan
Source/Credit: University of Auckland
Edited by: Scientific Frontline
Reference Number: nut100226_01
